»ó´Ü¿©¹é
±â»ç (Àüü 385°Ç)
[Late Breaking Studies] ¿À¸Þ°¡-3 Áö¹æ»ê ½ÉÇ÷°ü ÇýÅà ±Ù°Å ÃàÀû Áß ÀÓ¼¼Çü ±âÀÚ 2019-10-08 11:56
[Sub Story] Ç÷´ç ÀÇÁ¸¼º Àν¶¸° ¹ÝÀÀÀ¸·Î ¾ÈÀüÇÏ°í ¾ÈÁ¤µÈ Ç÷¾ÐÁ¶Àý. ÀÌ»óµ· ±âÀÚ 2019-08-08 14:01
[Sub Story] ¸ñÇ¥Ç÷´ç °í¼ö ½ÉÇ÷°ü ÇýÅà ¾à¹° ¾àÁø ÀÌ»óµ· ±âÀÚ 2019-08-08 13:43
[Sub Story] 4Á¦¿ä¹ý¿¡¼­ ¿¥Æı۸®Ç÷ÎÁø vs ´ÙÆı۸®Ç÷ÎÁø ÀÌ»óµ· ±âÀÚ 2019-08-08 13:38
[Sub Story] ¡°½ÉºÎÀü¡¤´ç´¢º´ ȯÀÚ¿¡ SGLT-2¾ïÁ¦Á¦¡± THE MOST 2019-08-08 13:25
¶óÀÎ
[Sub Story] Å׳׸®±Û¸³Æ¾, ¡®±º°èÀÏÇС¯ DPP-4¾ïÁ¦Á¦·Î ³ª¼³±î ÀÓ¼¼Çü ±âÀÚ 2019-08-08 13:09
[Sub Story] ¡®LDL-C¡¯ ÁÙÀÌ´Â DPP-4¾ïÁ¦Á¦ ¾Æ³ª±Û¸³Æ¾ ÀÓ¼¼Çü ±âÀÚ 2019-08-08 13:02
[Sub Story] ´ç´¢º´ ȯÀÚ LDLÄÝ·¹½ºÅ×·Ñ Á¶Àý °­ÇÏ°Ô ÀÌ»óµ· ±âÀÚ 2019-07-31 17:17
[Interview] DPP-4¾ïÁ¦Á¦ Ç÷´çº¯µ¿¼º¿¡ Ưȭ ÀÔÁõ ÀÌ»óµ· ±âÀÚ 2019-07-31 16:03
[Conference Report] ¿¡º¸±Û¸³Æ¾ A1C ³Ñ¾î Ç÷´çº¯µ¿¼ºµµ °³¼± ÀÓ¼¼Çü ±âÀÚ 2019-07-31 14:04
¶óÀÎ
[Sub Story] ¡°´ç´¢º´ÀÇ µ¶¸³ÀûÀÎ À§ÇèÀÎÀÚ¡± ÀÌ»óµ· ±âÀÚ 2019-07-31 10:28
[Conference Report] ¡°¿Ö ¿ì¸° 6.5% ¹Ì¸¸Àΰ¡?¡± ÀÌ»óµ· ±âÀÚ 2019-07-30 17:49
[Sub Story] ¼¼°è õ½ÄÀÇ ³¯À» ¸ÂÀÌÇÏ´Â ¿ì¸®ÀÇ ÀÚ¼¼: ±¹³» õ½Ä ¿ªÇÐ ¹× Ư¡ THE MOST 2019-07-02 17:49
[Drug Review] È£Èí±â Ä¡·á »õÈ°·Î ¸ð»öÇÑ´Ù ÀÌ»óµ· ±âÀÚ 2019-07-02 16:18
[Conference Report] ±¹³» ´ç´¢º´ ȯÀÚ ¸ñÇ¥Ç÷´ç ¡®6.5% ¹Ì¸¸¡¯ À¯Áö THE MOST 2019-07-02 14:46
¶óÀÎ
[Sub Story] ´ç´¢º´¡¤ÀÌ»óÁöÁúÇ÷Áõ µ¿¹ÝȯÀÚÀÇ LDLÄÝ·¹½ºÅ×·Ñ °­ÇÏÀü·« THE MOST 2019-03-28 15:39
[Conference Report] Ç÷ÀüÁ¦°Å¼ú ÈÄ ¼öÃà±âÇ÷¾Ð 140¡¤160mmHg ÀÌÇÏ Á¶ÀýÀÌ ÀûÀý ÀÓ¼¼Çü ±âÀÚ 2019-03-28 13:25
[Conference Report] ³úÁ¹Áß ÈÄ 24½Ã°£, ³ôÀº Ç÷¾Ðº¯µ¿¼ºÀÌ »ç¸ÁÀ§Çèµµ ³ôÀδ٠ÀÓ¼¼Çü ±âÀÚ 2019-03-28 13:20
[Cover Story] ³»ºÐºñ¡¤½ÉÀåÇа谡 ¹Ù¶óº¸´Â Ç÷´ç°­ÇÏÁ¦ ó¹æÀü·« ÀÌ»óµ· ±âÀÚ 2019-03-06 20:01
[Sub Story] ¡°¸ÞÆ®Æ÷¸£¹ÎÀ¸·Î ´ç´¢º´ ¿¹¹æ °¡´É¡± ÀÌ»óµ· ±âÀÚ 2019-03-06 19:56
Back to Top